Studies of Neurological Paraneoplastic Syndromes

March 27, 2009 updated by: Memorial Sloan Kettering Cancer Center
This study is for patients with cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome.

Study Overview

Status

Completed

Conditions

Detailed Description

Patients usually go to their doctors with neurological complaints and later find they have cancer, a known paraneoplastic syndrome, or neurological problems that suggest a paraneoplastic syndrome. Paraneoplastic syndromes are rare conditions in which the immune system is involved in causing brain damage and fighting cancer.

Such patients with paraneoplastic neurologic degenerations(PNDs) may have autoantibodies, an antibody or protein the immune system creates that is directed against his or her own proteins. This study aims to better understand PNDS by:

  • analyzing for autoantibodies in serum and cerebral spinal fluid
  • analyzing for antigen specificity and for antigens in cancer tissue
  • comparing PND autoantibodies with those in cancer patients but no PND
  • comparing PND autoantibodies with those in PND patients but no cancer
  • studying the immune performance of patients with PNDs

As this study is not a treatment study, tissues for this study will only come from procedures necessary for the patient's treatment.

Study Type

Observational

Enrollment (Actual)

51

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • New York
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients are selected from severals clinics within Memorial Sloan-Kettering Cancer Cetner

Description

Inclusion Criteria:

  • All adults are potentially eligible.

Exclusion Criteria:

  • None.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
1
One cohort group of patient with PNDS or suspected PNDS

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Increase understanding of PNDS
Time Frame: Ongoing
Ongoing

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Jerome Posner, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 1988

Primary Completion (Actual)

March 1, 2009

Study Completion (Actual)

March 1, 2009

Study Registration Dates

First Submitted

December 21, 2007

First Submitted That Met QC Criteria

December 21, 2007

First Posted (Estimate)

January 7, 2008

Study Record Updates

Last Update Posted (Estimate)

March 30, 2009

Last Update Submitted That Met QC Criteria

March 27, 2009

Last Verified

March 1, 2009

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 88-044

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Paraneoplastic Neurologic Degenerations (PNDs)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe